Aros

Noble Research Institute Achieves Agricultural Research Organization Status

Retrieved on: 
Tuesday, December 5, 2023
Internal Revenue Code, Agriculture, Research, Internal Revenue Service, Organization, Average revenue per user, Noble, Laboratory, Farmer, Health, Aros, IRS, University, Rhines, Soil, Government, Cryptocurrency, ARO

ARDMORE, Okla., Dec. 5, 2023 /PRNewswire-PRWeb/ -- Noble Research Institute has been recognized formally as a 501(c)(3) public charity by virtue of being an agricultural research organization (ARO) by the Internal Revenue Service, retroactive to Jan. 1, 2018. With this designation, Noble is now the largest independent ARO in the U.S.

Key Points: 
  • ARDMORE, Okla., Dec. 5, 2023 /PRNewswire-PRWeb/ -- Noble Research Institute has been recognized formally as a 501(c)(3) public charity by virtue of being an agricultural research organization (ARO) by the Internal Revenue Service, retroactive to Jan. 1, 2018.
  • With this designation, Noble is now the largest independent ARO in the U.S.
    "We are grateful for this final step in our journey to be recognized as an ARO," said Steve Rhines, president and CEO of Noble Research Institute.
  • "It has long been our goal to help build the public agricultural research capacity in the U.S. in ways that go beyond government funding."
  • "AROs provide public agricultural research a full complement of philanthropic tools to reach individuals and families and provide them a charitable vehicle to advance public agricultural research," Rhines said.

George Clinical Applauded by Frost & Sullivan for Its Competitive Differentiation and Leadership in Strategy Execution in the Asia Pacific region

Retrieved on: 
Thursday, May 4, 2023
Oncology, Chronic kidney disease, Aros, Clinical trial, ARO, Science, Interface (computing), Patient, SAN, Neurology, System, Clinical, ChromeOS, Pharmaceutical industry, Nursing

SAN ANTONIO, May 3, 2023 /PRNewswire/ -- Frost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award. George Clinical is a global CRO with world class expertise in Kidney research, Oncology and Neurology and remains fully committed to growing their strong presence in Asia-Pacific which is where the company has its roots. It operates on the central tenet that its success depends on customer satisfaction, so it provides a human touch to its projects. A sustainable skilled workforce inherently ensures quality outcomes for clients and patients. High employee retention rates also result in new hires through current employee referrals and, more importantly, lower project downtime risks, reducing potential costs from replacing and training new hires.  Unlike larger contract research organizations (CROs), the company promotes a healthy work-life balance for its employees where they do not operate like machines when executing a trial.

Key Points: 
  • George Clinical cares for its employees, enables business continuity, and builds on its expertise, giving it a competitive industry advantage.
  • SAN ANTONIO, May 3, 2023 /PRNewswire/ -- Frost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award.
  • It operates on the central tenet that its success depends on customer satisfaction, so it provides a human touch to its projects.
  • With its strong overall performance, George Clinical earns Frost & Sullivan's 2023 APAC Competitive Leadership Award in the contract research organization industry.

George Clinical Applauded by Frost & Sullivan for Its Competitive Differentiation and Leadership in Strategy Execution in the Asia Pacific region

Retrieved on: 
Thursday, May 4, 2023
Oncology, Chronic kidney disease, Aros, Clinical trial, ARO, Science, Interface (computing), Patient, SAN, Neurology, System, Clinical, ChromeOS, Pharmaceutical industry, Nursing

SAN ANTONIO, May 3, 2023 /PRNewswire/ -- Frost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award. George Clinical is a global CRO with world class expertise in Kidney research, Oncology and Neurology and remains fully committed to growing their strong presence in Asia-Pacific which is where the company has its roots. It operates on the central tenet that its success depends on customer satisfaction, so it provides a human touch to its projects. A sustainable skilled workforce inherently ensures quality outcomes for clients and patients. High employee retention rates also result in new hires through current employee referrals and, more importantly, lower project downtime risks, reducing potential costs from replacing and training new hires.  Unlike larger contract research organizations (CROs), the company promotes a healthy work-life balance for its employees where they do not operate like machines when executing a trial.

Key Points: 
  • George Clinical cares for its employees, enables business continuity, and builds on its expertise, giving it a competitive industry advantage.
  • SAN ANTONIO, May 3, 2023 /PRNewswire/ -- Frost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award.
  • It operates on the central tenet that its success depends on customer satisfaction, so it provides a human touch to its projects.
  • With its strong overall performance, George Clinical earns Frost & Sullivan's 2023 APAC Competitive Leadership Award in the contract research organization industry.

Opening the Digital Front Door in Clinical Trials to Improve Patient and Clinician Satisfaction, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, March 22, 2023
Aros, CHRC, SDV, MS, Openclinica, Division, Frustration, Astute, ChromeOS, Pharmaceutical industry

TORONTO, Ontario, Canada, March 22, 2023 /PRNewswire-PRWeb/ -- It's no secret that we live in a digital age, and the key to successful patient engagement and clinician satisfaction is technology. From both perspectives, people want to interact in clinical trials with the same ease and ownership they enjoy with banking, shopping and ordering lunch.

Key Points: 
  • In this free webinar, learn about the challenges, problems and opportunities related to the digital front door in clinical trials and how to overcome them.
  • The featured speakers will discuss the fiscal and outcome benefits of digital-first strategies in clinical trials.
  • A digital front door enables sponsors, CROs and AROs to improve patient and clinician satisfaction, data quality and control costs.
  • Featured speakers will discuss challenges, risks and opportunities in digital front door strategies for traditional, decentralized and hybrid trials.

physIQ Launches the Intrepid Partner Program

Retrieved on: 
Wednesday, November 9, 2022
Technology, Pharmaceutical, Health Technology, Oncology, Other Science, Artificial Intelligence, Research, Medical Devices, Infectious Diseases, Hospitals, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Practice Management, Wearables, Mobile Technology, Managed Care, Science, Nursing, Telemedicine, Virtual Medicine, FDA, Biometrics, Other Health, Aros, Temperature, Contract, ROI, Exercise, Medicine, Safety, Cros, Senior, Inflammation, Program, Wilson, Clinical trial, General manager, Patient, CPET, Nike Air Max, Industry, GeForce Partner Program, Medical imaging, Pharmaceutical industry

physIQ announced today the launch of its Intrepid Partner Program, designed to enable the Life Sciences solutions ecosystem to deliver next generation near real time patient insights powered by high-fidelity medical grade biosensor data streams in both clinical and remote patient settings.

Key Points: 
  • physIQ announced today the launch of its Intrepid Partner Program, designed to enable the Life Sciences solutions ecosystem to deliver next generation near real time patient insights powered by high-fidelity medical grade biosensor data streams in both clinical and remote patient settings.
  • The physIQ Intrepid Partner Program will provide a distinct advantage to its members when competing for the business of both large and small life science companies alike.
  • We are at an inflection pointAI will redefine patient safety standards, and physIQ is ready to bring these advances to the industry, said John Wilson, Senior Vice Present and General Manager of Life Sciences for physIQ.
  • The Intrepid Partner Program is designed to extend physIQs capabilities to the industry through participating Contract Research Organizations (CROs), Academic Research Organizations (AROs) and other technology solution companies.

OneNexus Secures Financing From Global Reinsurance Company Munich Re

Retrieved on: 
Tuesday, October 18, 2022
Other Energy, Insurance, Oil, Gas, Environmental, Social and Governance (ESG), Energy, Professional Services, Technology, Other Technology, Biophysical environment, ARO, ESG, LLC, Soil, Carbon, Aros, AA, Partnership, Groundwater, Goal, Group, KKR, Climate change, Environmental, social and corporate governance, Methane, Solution, Insurance, Risk management, Renewable energy, Munich Re

OneNexus, LLC and its wholly-owned captive insurance company, OneNexus Oklahoma Captive Corp. (OOCC), today announced that they have entered into a definitive agreement with Munich Re Energy Transition Finance (MRETF), a wholly-owned subsidiary of AA-rated global reinsurance company Munich Re AG for the purpose of providing backstop capital for OneNexus new Asset Retirement Obligation (ARO) funding product.

Key Points: 
  • OneNexus, LLC and its wholly-owned captive insurance company, OneNexus Oklahoma Captive Corp. (OOCC), today announced that they have entered into a definitive agreement with Munich Re Energy Transition Finance (MRETF), a wholly-owned subsidiary of AA-rated global reinsurance company Munich Re AG for the purpose of providing backstop capital for OneNexus new Asset Retirement Obligation (ARO) funding product.
  • MRETFs financial commitment, along with capital provided by OneNexus founding members, ensures sufficient capital for OneNexus to cover up to $1.2 billion in ARO liabilities.
  • Vikram Nath, Managing Director, Munich Re Energy Transition Finance, comments, The transaction with OneNexus demonstrates our unwavering commitment to energy transition.
  • ABOUT MUNICH RE / MUNICH RE ENERGY TRANSITION FINANCE:
    Munich Re is one of the worlds leading providers of reinsurance, primary insurance and insurance-related risk solutions.

Edison Partners Leads USD $30M Investment in Field Effect

Retrieved on: 
Tuesday, October 4, 2022
Finance, Security, Professional Services, Technology, Software, Solution, Investment, University, LinkedIn, Research, SME, Government, Industry, Knowledge, Silicon, Aros, CEO, Chief executive officer, Michigan Cyber Range, MDR, Budget, Partner, Element, Dentons, Telemetry, Machine learning, Risk, Fortune 1000, Organization, Marketing, Software as a service, Risk management, Covalent bond, Field effect, Thomas Edison

Edison Partners , a leading growth equity investment firm, today announced a USD $20 million investment in Field Effect , an Ottawa-based global cyber security company specializing in intelligence-grade protection for small and medium organizations.

Key Points: 
  • Edison Partners , a leading growth equity investment firm, today announced a USD $20 million investment in Field Effect , an Ottawa-based global cyber security company specializing in intelligence-grade protection for small and medium organizations.
  • Edison Partners leads the $30 million round, joined by other strategic investors, who have contributed a combined $10 million.
  • Field Effect was founded with the purpose of addressing the cyber security needs of the vastly underserved small and medium enterprise (SME) market.
  • Field Effect is excited to work with Edison Partners to help scale our sales and marketing efforts and expand into new markets.

Datagration and OneNexus Environmental Collaborate to Address the Trillion-Dollar Problem of Aging Oil and Gas Well Infrastructure

Retrieved on: 
Tuesday, August 16, 2022
Technology, Finance, Fintech, Oil, Gas, Professional Services, Software, Energy, Environmental, Social and Governance (ESG), Data Management, Nexus, Social Security Government Pension Offset, Environmental, social and corporate governance, O&G, Hydrocarbon, Asset retirement obligation, Industry, Social, CEO, Retirement, Software as a service, ESG, Nicknames of Houston, Chief executive officer, KPI-driven code analysis, Engineering, Risk management, Company, Benchmarking, Data analysis, BI, Gas, Aros, The Benefit Company, Solution, UDM, Biophysical environment, Efficiency, Renewable energy

The Environmental, Social and Governance (ESG) of this problem is gaining attention from every aspect of the business and investment world.

Key Points: 
  • The Environmental, Social and Governance (ESG) of this problem is gaining attention from every aspect of the business and investment world.
  • Properly planning for the decommissioning of existing and future end-of-life wells is an important part of achieving oil & gas sustainability.
  • Datagration provides the world's Oil and Gas companies with the tools they need to integrate and model data into meaningful insights and decisions daily.
  • OneNexus Environmental was created to help oil & gas companies systematically and responsibly manage their Asset Retirement Obligations (AROs) and decommissioning activities.

Global Infection Surveillance Solutions Market Report (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 7, 2022
Software, Technology, Infectious Diseases, Health, Surgical incision, Subclinical infection, Infection, Eyeish, Time-invariant system, Software, Nursing, Solution, National Association Medical Staff Services, Growth, EHR, Patient, Hospital, Technology, Data management, Ventilator-associated pneumonia, COVID-19, Adoption, Prevalence, Epidemic, Industry, Collection, Aros, Safety, Pharmaceutical industry, Vaccine

In addition, the growing geriatric population and the increasing number of surgeries worldwide are positively influencing the market of infection surveillance solutions.

Key Points: 
  • In addition, the growing geriatric population and the increasing number of surgeries worldwide are positively influencing the market of infection surveillance solutions.
  • Key Questions Answered in This Report:
    How has the global infection surveillance solutions market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global infection surveillance solutions market?
  • What is the structure of the global infection surveillance solutions market and who are the key players?